Popular Articles
Natural Remedies

Identifiication Of Enzyme That Makes Survival Molecule For Key Vision Cells
Research lead by Dr. Nicolas Bazan, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, identifying an enzyme that makes neuroprotectin D1 which specifically and selectively protects retinal cells key for vision, was published in the June 26, 2009 issue of the Journal of Biological Chemistry.
generic viagra online
ACMG Joins Lawsuit Challenging Patents On Breast Cancer Genes
The American College of Medical Genetics (ACMG) has joined the Association for Molecular Pathology, the College of American Pathologists, and the American Society for Clinical Pathology in a lawsuit filed today charging that patents on the human genes associated with breast and ovarian cancer interfere with diagnostic testing, stifle research and limit women"s options regarding their health care. The lawsuit challenges patents on the BRCA1 and BRCA2 genes, which are responsible for most cases of hereditary breast and ovarian cancers. Because these genes are "products of nature," the ACMG believes that granting patents on them is illegal.
News of the day
Hospital Doctors Must Learn About Money To Drive Better Treatment And NHS Efficiency, UK
Hospital doctors must learn the basics of NHS finance to help drive greater efficiency and better outcomes for patients, according to the Academy of Medical Royal Colleges and the Audit Commission.
Mental Health

Vaccine Maker To Give 100 Million Swine Flu Shots To WHO

Sanofi-aventis, a French global healthcare company that makes vaccines announced on Wednesday that it will be giving the World Health Organization (WHO) 100 million doses of vaccine for H1N1 swine flu so it can distribute them to the countries that most need them. Sanofi-aventis Chief Executive Officer Christopher A Viehbacher told the opening session of the Pacific Health Summit in Seattle, Washington that he wanted to back WHO Director General"s call for common action. "Exceptional times require exceptional responses. We need to act responsibly and we all have to play our part," said Viehbacher. "That is the reason why we intend to donate 100 million doses of influenza vaccine to the World Health Organization (WHO) to help developing countries face the influenza pandemic," he added. Although the WHO says it has now received reports of nearly 40,000 worldwide lab-confirmed cases of novel A(H1N1) swine flu, including 167 deaths, and has raised the status level to phase 6, indicating global pandemic, the organization has not yet said anything about who should get vaccinated. Also, because this strain has not infected people before, it is not clear if one or two doses will be needed to achieve full immunization. Vaccine producers are just coming to the end of producing seasonal flu vaccine, after which they will start making vaccine against the new swine flu virus. It will be several weeks before the first batches are ready, which is probably too late for countries in the southern hemisphere who are about to enter the height of their annual flu season. Swine flu is now reaching southern countries that have not reported cases before. Earlier today South Africa joined the list, with a new case of swine flu in a 12-year old boy recently returned from the US. WHO estimate world capacity to produce swine flu vaccine is about 4.9 billion, which is not enough to vaccinate a world population of 6.5 billion, and if two shots are needed, then it will barely reach half that number. Viehbacher said that sanofi-aventis will reserve 10 per cent of its swine flu vaccine for the WHO to help developing countries fight the pandemic. Over and above the 100 million doses it will donate, the company will offer additional doses at discounted prices to developing countries, depending on production capacity, reported the Associated Press. British drugmaker GlaxoSmithKline said they will do the same, and have offered to donate 50 million doses of swine flu vaccine for the WHO to distribute to developing countries. They said last week that they would be ready to start large scale production within weeks. According to the AP report, Novartis, another major vaccine maker based in Switzerland have decided not to go down the donation route. Company spokesman Eric Althoff said on Wednesday that the company would prefer to find a more sustainable way to support developing countries than one time donations. They are considering selling vaccines at discounted prices instead, he said. s: Sanofi Aventis, AP. Written by: Catharine Paddock, PhD Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):